| Summary |
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease in the human motor system characterized by the selective involvement of spinal cord anterior horn cells, brainstem motor nuclei, and the corticospinal tract. It predominantly presents as concurrent damage to upper and lower motor neurons.
Induced pluripotent stem cells (iPSCs) are a type of induced pluripotent stem cell derived from autologous or allogeneic cell sources. They can differentiate into various functional cell types, including specific motor neuron cells. iPSCs are used for stem cell replacement therapy. iPSCs hold significant clinical potential for ALS treatment. The iPSC database with human leukocyte antigen characteristics may represent a promising technology. This technology has the potential to obtain high-quality cell products and reduce the risk of graft rejection. Moreover, human iPSCs have demonstrated a certain degree of efficacy in the transplantation of neural stem/progenitor cells derived from ALS rodent models.
The potential mechanisms of iPSC therapy for ALS include: the differentiated motor neuron precursor cells can replace damaged motor neurons, and restore motor conduction function; by secreting neurotrophic factors, they protect neurons; through immune regulation, they inhibit inflammatory reactions, and slow the progression of ALS.
Xellsmart Biomedical (Suzhou) Co., Ltd. is developing an injectable solution for ALS treatment using human iPSC-derived motor neuron precursor cells to address the pressing need for ALS therapy. |
| Description |
This study is a non-randomized, open-label, multiple-dose, investigator-initiated interventional clinical trial aimed at preliminary exploring the safety of the investigational drug. The study is divided into three phases: a baseline period (7 days), a treatment period (45 days), and a follow-up period (6 months).
Baseline Period: The ALS subjects need to sign the informed consent form for the clinical trial (including the installation surgery for the Sofia drug pouch) and undergo baseline assessments before the transplant surgery to exclude any conditions that would disqualify them from participation. The subjects need to undergo medical history collection, vital signs and physical examinations, laboratory tests, various other auxiliary examinations, and perform self-assessment of their physical condition. The investigator records clinical symptoms, scores and records various scales and tables. [including ALS Functional Rating Scale-Revised (ALSFRS-R), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAMD 17), Hamilton Anxiety Rating Scale (HAMA), Fatigue Severity Scale (FSS)]. Qualified subjects will subsequently take oral immunosuppressants for three months, and the clinical research investigator will adjust the dosage and medication duration based on the subjects' rejection response and tolerability.
Treatment Period: At Day -3 of the treatment period, the surgical expert administers general anesthesia to the subjects and, under the guidance of a robot, installs the Sofia drug pouch. On the first day post-surgery, through head CT and other examinations, adverse events (AEs and SAEs) are assessed. On Treatment Day 0 (i.e., 3 days post-surgery), the first stem cell transplantation begins. Subjects undergo vital sign monitoring, physical examinations, and record self-assessments of their physical condition and clinical symptoms before undergoing intraventricular stem cell transplantation. The investigator injects 2 mL of human iPSC-derived motor neuron precursor cells (5×107 cells) through the subcutaneous drug pouch. Subsequently, the same dose of stem cells is administered through the drug pouch every half month, totaling four times. After the administration, subjects are advised to lie flat for one hour, with simultaneous monitoring of vital signs and blood oxygen saturation, and recording of any possible adverse events (AEs and SAEs). On the third day after each stem cell transplantation treatment, subjects undergo safety assessments (vital signs, physical examinations, laboratory tests, 12-lead electrocardiogram, cerebrospinal fluid routine, ultrasound, and imaging examinations, etc.) and an evaluation of the impact of this study on the efficacy of individual ALS subjects (patient self-assessment of condition and clinical symptoms, scales [ALSFRS-R, MMSE, MoCA, HAMD 17, HAMA, FSS], electrophysiological parameter testing, FVC, and cerebrospinal fluid neurotrophic factor detection).
Follow-up Phase: Subjects return to the clinical research center for safety and effectiveness assessments at 1 month, 3 months, and 6 months after finishing all the stem cell transplantations (i.e., 2.5 months, 4.5 months, and 7.5 months after the first stem cell transplantation). For subjects who do not complete all four stem cell transplantations, the follow-up schedule is adjusted based on the completion time of the stem cell transplantation. For safety reasons, the next subject can only be enrolled after the previous subject has completed the stem cell transplantation and been observed for 6 months without the occurrence of acute or delayed SAEs. The clinical research center should be equipped to handle unexpected acute, severe adverse events, such as allergic reactions and medication-related reactions. |
